Event Recordings
Session 1 - Drug Discovery I
Drug Discovery - By Design, Not By Chance
Alistair Henry, PhD
Executive Vice President & CSO, UCB
Beyond Biology: Building Decision Systems for Scalable Drug Discovery
Mike Quigley, PhD
CSO and Global Head of Research, Sanofi
Panel Discussion
Moderator: Michelle Longmire, MD
Facilitator: Sanjay Malhotra, PhD
Mike Quigley, PhD
CSO and Global Head of Research, Sanofi
Karen Akinsanya, PhD
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships, Schrödinger
Alistair Henry, PhD
Executive Vice President & CSO, UCB
Session III - VC Perspective: Investing in Early-Stage Innovation
Panel Discussion
Moderator: Joe Jimenez, MBA
Facilitator: Mark Mercola, PhD
Amit Sinha, MBA
Partner, CIO and Global Head of Life Sciences Investing, Goldman Sachs
Vijay Pande, PhD
Co-Founder and Managing Partner, VZVC
Tom Hudson, MD
Venture Partner, Versant Ventures
Rajeev Dadoo, PhD
COO and Managing Partner, SR One
Session V - Presentation of Lifetime Achievement Award Lecture
Cellular Therapy for Solid Epithelial Cancers
Steven Rosenberg, MD, PhD
Chief, Surgery Branch,
Center for Cancer Research,
National Cancer Institute, NIH
The Improbable History of CAR T Cells
Carl June, MD
Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine; Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine; Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania
Panel Discussion
Moderated by Lloyd Minor, MD
Steven Rosenberg, MD, PhD
Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH
Michel Sadelain, MD, PhD
Herbert and Florence Irving Professor of Medicine;
Director, Columbia Institute for Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University
Carl June, MD, PhD
Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine; Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine; Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania
Session VII - Drug Discovery III
The Future of Obesity Medicine
Kenneth Custer, PhD
EVP and President, Lilly Cardiometabolic Health, Eli Lilly and Company
Panel Discussion
Moderated by Michael Quigley, PhD
Facilitator: Kuldev Singh, MD
Anthony Adamis, MD
Co-Founder, Director, CSO, EyeBio, a Merck Company
Kenneth Custer, PhD
EVP and President, Lilly Cardiometabolic Health, Eli Lilly and Company
Jay Bradner, MD
Executive Vice President, Research and Development, Amgen
Session IX - Drug Discovery IV
Eliminating Pathogenic Mechanisms via Multiple Levers and Sources
Flavius Martin, MD
Executive Vice President of Research, Gilead